Results 131 to 140 of about 110,851 (248)

Evidence for investigating GSK-3 inhibitors as potential therapeutics for severe COVID-19. [PDF]

open access: yesBiochem Biophys Res Commun, 2022
Ghazanfari D   +5 more
europepmc   +1 more source

Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.
The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies   +23 more
wiley   +1 more source

PB2203: INCIDENCE AND PREVALENCE OF MYELOFIBROSIS IN GERMANY: A RETROSPECTIVE CLAIMS DATA ANALYSIS

open access: yesHemaSphere, 2023
Sophia Junker   +10 more
doaj   +1 more source

Systematic statistical analysis of change in SEIzure interVAL with diazepam nasal spray supports this novel clinical endpoint for immediate‐use seizure medication

open access: yesEpilepsia, EarlyView.
Abstract Objective Appropriate endpoints for daily antiseizure medications may differ from those for intermittent, immediate‐use seizure medications (ISMs). The observed interval between seizure clusters over time (SEIzure interVAL [SEIVAL]) has been proposed as a novel effectiveness endpoint for ISMs.
Wesley T. Kerr   +4 more
wiley   +1 more source

Predicting seizure freedom in the postpartum period: Findings from the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs study

open access: yesEpilepsia, EarlyView.
Abstract Objective This study was undertaken to evaluate whether seizure freedom in pregnancy predicts seizure freedom in the postpartum period in women with epilepsy (WWE). Prior studies have shown that seizure freedom prior to conception strongly predicts seizure freedom during pregnancy.
Emma C. Osterhaus   +7 more
wiley   +1 more source

Cannabidiol reduces atypical absence seizures and epileptic spasms in a Gabrb3+/D120N mouse model of Lennox–Gastaut syndrome

open access: yesEpilepsia Open, EarlyView.
Abstract Objective Lennox–Gastaut syndrome (LGS) is a drug‐resistant developmental and epileptic encephalopathy (DEE). Preclinical drug development for LGS is constrained by a lack of syndrome‐relevant animal models. We aimed to evaluate a Gabrb3+/D120N knock‐in (KI) mouse model of LGS by quantifying atypical absence seizures and epileptic spasms and ...
Thomas Harman   +5 more
wiley   +1 more source

Recent Perspectives on Phytochemical Profile, Pharmacological Activities, and Industrial Applications of Guava (Psidium guajava)

open access: yesFood Safety and Health, EarlyView.
Psidium guajava leaves contain potent bioactive compounds like quercetin, myricetin, and triterpenoids that show antioxidant, antidiabetic, anti‐inflammatory, and anticancer effects. They act by modulating NF‐κB, PPARγ, and α‐glucosidase and by inducing apoptosis and cell cycle arrest.
Muhammad Waqar   +10 more
wiley   +1 more source

Disease Site‐Specific Outcomes in p16‐Positive Non‐Oropharyngeal Mucosal Head and Neck Cancer

open access: yesHead &Neck, EarlyView.
ABSTRACT Objectives To report disease‐free survival (DFS) in p16‐positive non‐oropharyngeal head‐and‐neck squamous‐cell carcinoma (HNSCC). Methods Curatively‐treated non‐oropharyngeal HNSCC (2009–2021) were reviewed. DFS was compared among p16‐positive, p16‐negative, and p16‐untested cases for the overall cohort and by disease site.
Revadhi C. Chelvarajah   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy